The derivative suit didn’t establish any wrongdoing by the company’s directors or top executives, and the plaintiff failed to demand an internal investigation before filing it, Judge Charles R. Breyer said.
McKesson, one of the “big three” U.S. pharmaceutical wholesalers, has been drawn into multiple lawsuits and investigations that primarily blame top drugmakers for the alleged industry-wide scheme. But it hasn’t faced any criminal charges or civil enforcement suits,…
